Addex Therapeutics Ltd(ADXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADXN Addex Therapeutics Ltd

Trading 12-11 14:15:58 EST

7.81

-0.09

-1.14%

High7.84	Low7.81	Vol4.55K
Open7.84	D1 Closing7.90	Amplitude0.38%
Mkt Cap9.61M	Tradable Cap8.14M	Total Shares1.23M
T/O35.59K	T/O Rate0.44%	Tradable Shares1.04M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADXN","market":"US","secType":"STK","nameCN":"Addex Therapeutics Ltd","latestPrice":7.81,"timestamp":1765478458067,"preClose":7.9,"halted":0,"volume":4545,"delay":0,"floatShares":1041800,"shares":1231100,"eps":11.971627,"marketStatus":"Trading","change":-0.09,"latestTime":"12-11 14:15:58 EST","open":7.84,"high":7.84,"low":7.81,"amount":35588.46807,"amplitude":0.003797,"askPrice":8.66,"askSize":100,"bidPrice":7.48,"bidSize":1,"shortable":3,"etf":0,"ttmEps":11.971627,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765486800000},"marketStatusCode":2,"adr":0,"adrRate":120,"exchange":"NASDAQ","adjPreClose":7.9,"preHourTrading":{"tag":"盘前","latestPrice":7.95,"preClose":7.9,"latestTime":"09:08 EST","volume":245,"amount":1945.3135730000001,"timestamp":1765462135488},"postHourTrading":{"tag":"盘后","latestPrice":7.9,"preClose":7.9,"latestTime":"19:26 EST","volume":295,"amount":2119.99,"timestamp":1765412773205},"volumeRatio":1.993095},"requestUrl":"/m/hq/s/ADXN","defaultTab":"news","newsList":[{"id":"2584975296","title":"Addex Therapeutics files to sell $150M in ordinary shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584975296","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584975296?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:05","pubTimestamp":1763586343,"startTime":"0","endTime":"0","summary":"16:02 EST Addex Therapeutics (ADXN) files to sell $150M in ordinary shares Published first on TheFly – the ultimate source for real-time, market-mo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/addex-therapeutics-files-to-sell-150m-in-ordinary-shares-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/addex-therapeutics-files-to-sell-150m-in-ordinary-shares-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADXN","LENZ","BK4539","BK4007","BK4139"],"gpt_icon":0},{"id":"2576061348","title":"ADRs Hold Steady; Addex Therapeutics Ltd. Climbs 28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576061348","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576061348?lang=en_us&edition=fundamental","pubTime":"2025-10-18 04:30","pubTimestamp":1760733000,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed flat on Friday, as the S&P/BNY Mellon index of American depositary receipts was flat at 227.79.The European index added 0.3% to 198.73. The Asian index fell 0.2% to 309.91. The Latin American index rose 0.5% to 214.48, while the emerging-markets index fell 0.4% to 518.77.Switzerland's Addex Therapeutics Ltd. was the biggest leader during the session, rocketing 28% to $10.95, and Japan-based LEIFRAS Co. Ltd. soared 24% to $4.20. XCHG Ltd., which is based in China, rounded out the top three leaders on Friday, with shares jumping 16% to $1.76.Evaxion A/S, based in Denmark, posted the largest decline, plummeting 29% to $6.79, followed by shares of China's Lixiang Education Holding Co. Ltd., which plunged 18% to 32 cents. Shares of China-based 9F Inc. tumbled 16% to $3.75.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ADXN"],"gpt_icon":0},{"id":"2571933397","title":"Press Release: Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2571933397","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571933397?lang=en_us&edition=fundamental","pubTime":"2025-09-30 13:00","pubTimestamp":1759208400,"startTime":"0","endTime":"0","summary":"-- Cash position of CHF 2.3 million at end of H1 2025. -- GABAB PAM chronic cough candidate demonstrated robust anti-tussive. -- Regained rights to phase 2 mGlu2 PAM asset, ADX71149. -- Indivior advanced GABAB PAM substance use disorders program successfully. -- Entered option agreement with Sinntaxis for exclusive license to. intellectual property covering the use of mGlu5 NAM in brain injury. -- Invested in Stalicla SA, confirming commitment to advancing innovative. Geneva, Switzerland, September 30, 2025 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended June 30, 2025, and provided a corporate update.-- Indivior advanced its GABAB PAM program for substance use disorders. intellectual property covering use of mGlu5 NAM in brain injury recovery. -- Invested in Stalicla, continu","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4007","BK4139","ADXN"],"gpt_icon":0},{"id":"2568414701","title":"ADRs Advance; Addex Therapeutics Ltd. Climbs 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568414701","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568414701?lang=en_us&edition=fundamental","pubTime":"2025-09-18 04:30","pubTimestamp":1758141000,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed higher on Wednesday, as the S&P/BNY Mellon index of American depositary receipts gained 0.6% to 222.48.The European index added 0.2% to 193.78. The Asian index gained 1.0% to 302.85. The Latin American index rose 0.4% to 215.89, while the emerging-markets index gained 1.1% to 498.27.Switzerland's Addex Therapeutics Ltd. was the biggest leader during the session, jumping 16% to $10.85, and China-based 17 Education & Technology Group Inc. surged 15% to $3.55. Valneva SE, which is based in France, rounded out the top three leaders on Wednesday, with shares jumping 12% to $9.97.Huize Holding Ltd., based in China, posted the largest decline, cratering 21% to $3.06, followed by shares of China's MOGU Inc., which tumbled 16% to $4.20. Shares of Israel-based Steakholder Foods Ltd. plunged 11% to $4.89.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADXN","BK4139"],"gpt_icon":0},{"id":"2557323173","title":"Earnings Flash (ARDX) Ardelyx Q2 Loss $0.08 Vs. FactSet Est. $0.13 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2557323173","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557323173?lang=en_us&edition=fundamental","pubTime":"2025-08-05 05:39","pubTimestamp":1754343573,"startTime":"0","endTime":"0","summary":"Earnings Flash (ARDX) Ardelyx Q2 Loss $0.08 Vs. FactSet Est. $0.13 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADXN","ARDX"],"gpt_icon":0},{"id":"2544113742","title":"Addex Therapeutics Q1 EPS $(1.33) Up From $(1.37) YoY, Sales $78.93K Down From $268.83K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2544113742","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544113742?lang=en_us&edition=fundamental","pubTime":"2025-06-19 14:39","pubTimestamp":1750315194,"startTime":"0","endTime":"0","summary":"Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(1.33) per share. This is a 2.92 percent increase over losses of $(1.37) per share from the same period last year.  The company reported $78.93 thousand in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/06/46011449/addex-therapeutics-q1-eps-1-33-up-from-1-37-yoy-sales-78-93k-down-from-268-83k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ADXN"],"gpt_icon":0},{"id":"2544194106","title":"Press Release: Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2544194106","media":"Dow Jones","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544194106?lang=en_us&edition=fundamental","pubTime":"2025-06-18 13:00","pubTimestamp":1750222800,"startTime":"0","endTime":"0","summary":"Title:   Addex Therapeutics Q1 2025 financial results and corporate update. the link provided below. Upon registering, each participant will be. provided with Participant Dial-in numbers, and a unique Personal PIN.to use the conference access information provided in the e-mail received. at the point of registering. Participants may also use the call me. feature instead of dialing the nearest dial in number.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","HST","BK4181","ADXN","LENZ","BK4139","BK4585","BK4539","BK4588","BK4007"],"gpt_icon":0},{"id":"2542356405","title":"European Equities Traded in the US as American Depositary Receipts Rise Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2542356405","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542356405?lang=en_us&edition=fundamental","pubTime":"2025-06-11 23:19","pubTimestamp":1749655191,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were rising on Wednesday morning, up 0.5% to 1,497.69 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by pharmaceutical company Addex Therapeutics  and advertising company Criteo , which rose 5.1% and 2% respectively.They were followed by energy company Eni , up 1.4%.The decliners from continental Europe were led by biotech companies Abivax  and Evaxion , which fell 2.9% and 2% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical company Verona Pharma  and biotech firm Bicycle Therapeutics , which gained 4.8% and 3.9% respectively.They were followed by biotech company Barinthus Biotherapeutics , which added 2%.The decliners from the UK and Ireland were led by biotech firms Akari Therapeutics  and Autolus Therapeutics , which dropped 3.5% and 3.2% respectively.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADXN","CRTO","EVAX","BK4139","AKTX","BK4117","BK4201","IE00BFMHRM44.USD","VRNA","E","BRNS","BK4107","AFG","BK4009","BK4007","ABVX","BCYC","AUTL","BK4539"],"gpt_icon":0},{"id":"2542345933","title":"European Equities Traded in the US as ADRs Rise Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2542345933","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542345933?lang=en_us&edition=fundamental","pubTime":"2025-06-10 23:17","pubTimestamp":1749568664,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts rose Tuesday morning with the S&P Europe Select ADR Index up 0.6% to 1,491.03.From continental Europe, the gainers were led by biopharmaceutical firm DBV Technologies  and energy company Equinor , which rose 6.6% and 2.3% respectively.They were followed by energy firm Eni , up 1.8%.The decliners from continental Europe were led byclinical-stage pharmaceutical company Addex Therapeutics  and cybersecurity firm Wisekey , which fell 13% and 5.4% respectively.They were followed by medical device company Edap , down 3.3%.From the UK and Ireland, the gainers were led by software development company Endava  and biotech company Bicycle Therapeutics , which rose 4.2% and 3.4% respectively.The decliners from the UK and Ireland were led by bitcoin mining company Argo Blockchain  and financial institution Barclays , which lost 4.3% and 2.5% respectively.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADXN","DAVA","BK4207","BK4134","LU0648005311.SGD","BK4585","DAVA.AU","BK4521","BK4588","E","BK4139","LU0084288595.USD","BCS","DBVT","WKEY","BK4201","BCYC","BK4595","BK4023","BK4565","BK4007","BK4141","EQNR","BK4082","EDAP","BK4600","ARBK"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.addextherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1212},{"period":"1month","weight":-0.0728},{"period":"3month","weight":-0.1002},{"period":"6month","weight":-0.0576},{"period":"1year","weight":-0.0125},{"period":"ytd","weight":0.1286}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.244494},{"month":2,"riseRate":0.333333,"avgChangeRate":0.115434},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.133714},{"month":4,"riseRate":0.5,"avgChangeRate":-0.084878},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045376},{"month":6,"riseRate":0.5,"avgChangeRate":-0.090557},{"month":7,"riseRate":0.666667,"avgChangeRate":0.007044},{"month":8,"riseRate":0.333333,"avgChangeRate":0.10966},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.0989},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.063794},{"month":11,"riseRate":0,"avgChangeRate":-0.116863},{"month":12,"riseRate":0.5,"avgChangeRate":0.00149}],"exchange":"NASDAQ","name":"Addex Therapeutics Ltd","nameEN":"Addex Therapeutics Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Addex Therapeutics Ltd(ADXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Addex Therapeutics Ltd(ADXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Addex Therapeutics Ltd,ADXN,Addex Therapeutics Ltd股票,Addex Therapeutics Ltd股票老虎,Addex Therapeutics Ltd股票老虎国际,Addex Therapeutics Ltd行情,Addex Therapeutics Ltd股票行情,Addex Therapeutics Ltd股价,Addex Therapeutics Ltd股市,Addex Therapeutics Ltd股票价格,Addex Therapeutics Ltd股票交易,Addex Therapeutics Ltd股票购买,Addex Therapeutics Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Addex Therapeutics Ltd(ADXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Addex Therapeutics Ltd(ADXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}